Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Institute for International Health Professions Education and Research, China Medical University, Shenyang, 110122, Liaoning, China.
Syst Rev. 2021 Dec 6;10(1):306. doi: 10.1186/s13643-021-01863-7.
There are limited data on the clinical benefits of adding surgical resection in patients with recurrent or metastatic gastrointestinal stromal tumors (GISTs). This protocol outlines the planned scope and methods for a systematic review and meta-analysis update that will compare the clinical outcomes of surgical resection combined with tyrosine kinase inhibitor (TKI) with TKI treatment alone in patients with recurrent or metastatic GISTs.
This review will update a previously published systematic review by our team. This protocol is presented in accordance with the PRISMA-P guideline. PubMed, Embase, and Cochrane Central Register of Controlled Trials will be systematically searched and supplemented by a secondary screening of the references of all included studies. We will include randomized controlled trials (RCTs) and non-randomized studies (NRS) in this review update. The outcomes evaluated will be overall survival and progression-free survival. Two reviewers will independently screen and select studies, extract data from the included studies, and assess the risk of bias of the included studies. Data extracted from RCTs and NRS will be analysed and reported separately. Preplanned subgroup analyses and sensitivity analyses are detailed within this protocol. The strength of the body of evidence will be assessed using GRADE.
This systematic review and meta-analysis update will provide a current assessment of the evidence for the role of surgery in patients with recurrent or metastatic advanced GISTs. These findings will be used by the Chinese Society of Clinical Oncology (CSCO) GIST guideline recommendations on surgical treatment for recurrent or metastatic advanced GIST patients in China.
This protocol was prospectively registered in the Open Science Framework Registry ( https://osf.io/xus7m ).
在复发性或转移性胃肠道间质瘤（GIST）患者中，添加手术切除的临床获益数据有限。本方案概述了一项系统评价和荟萃分析更新的计划范围和方法，该更新将比较复发性或转移性 GIST 患者手术切除联合酪氨酸激酶抑制剂（TKI）与单独 TKI 治疗的临床结局。
本综述将更新我们团队之前发表的系统评价。本方案按照 PRISMA-P 指南呈现。将系统地搜索 PubMed、Embase 和 Cochrane 对照试验中心注册库，并对所有纳入研究的参考文献进行二次筛选。本综述更新将纳入随机对照试验（RCT）和非随机研究（NRS）。评估的结局将是总生存期和无进展生存期。两名审查员将独立筛选和选择研究，从纳入研究中提取数据，并评估纳入研究的偏倚风险。从 RCT 和 NRS 中提取的数据将分别进行分析和报告。本方案详细说明了预先计划的亚组分析和敏感性分析。使用 GRADE 评估证据的强度。
本系统评价和荟萃分析更新将对手术在复发性或转移性晚期 GIST 患者中的作用提供当前的证据评估。这些发现将用于中国临床肿瘤学会（CSCO）GIST 指南对中国复发性或转移性晚期 GIST 患者手术治疗的建议。
本方案在开放科学框架注册库（https://osf.io/xus7m）中进行了前瞻性注册。
